The company activity began from Innovita Research Foundation, a private foundation, which from 2001 was helping researchers working in the field of anti-aging medicine. At 2005 the foundation was re-structurized to Innovita Research company. During 16 years activity, Innovita Research performed and initiated a number of scientific projects in anti-aging medicine, immunotherapeutic approach for cancer treatment and regenerative medicine, which resulted in a number of scientific papers, patents and developed technologies.
Cancer Immunotherapy - the purpose of immunotherapy is to stimulate antitumor immune responses and to generate a long-term antitumor immune memory in cases when natural anti-tumor defense mechanisms are insufficiently effective, such as in advanced cancer patients.
T-Cell Immunotherapy (T-Cell Vaccination) for Autoimmune and Allergic Disorders - T-lymphocytes play a pivotal role in adaptive immunity. Pathogenic T cell activity is instrumental to the development of acquired immunological disorders. Self-reactive T lymphocytes able to attack host tissues induce autoimmune inflammation. High activity of allergen-specific T lymphocytes underlies the pathogenesis of allergic diseases.
Adoptive cell-based immunotherapy for chronic inflammatory diseases - based on the introduction of activated (instructed) immune cells with a high microbicidal activity directly into the focus of a chronic infection. Recurrence of the disease may be an indication for a repeat procedure.
OPI therapy for motor and skin diseases - OPI therapy is a complex treatment that simultaneously includes an orthokine (serum) therapy, a PrP (platelet) therapy and a leucocyte-based immunotherapy.
Storage of immune cells - a technology of cell cryopreservation allows for application of healthy autologous immune cells when the protective abilities of the body are reduced as a consequence of aging or disease.
Innovita Research also offers high quality pre-clinical trials service of any kind of customer substance , device or technology.
Victor Seledtsov, Prof., M.D., Ph.D., is the Director at Innovita Research (from 2013). He is also a scientist working in the fields of immunology and allergology. Victor Seledtsov has received his M.D. in 1983 from Tomsk Medical University and continued his postgraduate studies in the Russian Academy of Medical Sciences in Moscow. In 1987 he has received a Ph.D. degree in immunology and continued habilitation and post-doctoral research in immunology, oncology and regenerative medicine, which resulted in Doctor of Medical Sciences degree in immunology in 1998. Also, in 1998, he performed studies at Proneuron, Inc. (Rockville, MD, USA), focusing on the immunobiological properties of the erythroid cell-derived suppressor factor (ESF).
Adas Darinskas, Ph.D., is a biotechnologist keen on cell technologies. After graduating the Vilnius University faculty of Natural Sciences, he got a master in molecular biology and defeated his Ph.D. theses in Immunology in the year 2008. The year 2015-2016 he graduated master program: Master degree in manufacturing of advanced therapy medicinal products, specialisation as qualified person (1,647 hours) related to the Master Programme in Manufacturing of Advanced Therapy Medicinal Products (Universidad de Granada/Iniciativa Andaluza en Terapias Avanzadas).
Eglė Žūlinaitė, M.Sc., is a biotechnologist and QA specialist. She achieved her Bachelor’s degree in Chemical Engineering field at the Kaunas University of Technology in 2013. Also, she has a Master’s degree in biotechnology which she gained in 2016 at Vilnius Gediminas Technical University.
Jan Kraśko, Ph.D., has started his grownup research career in 2011, when he graduated from the Warsaw University of Life Sciences in Poland with Master Engineer in Biotechnology degree. He did internship in the National Institute of Public Health in Warsaw, where he gained knowledge of the daily routine of an analytical laboratory. He performed research in the National Medicines Institute, Laboratory of Virology, which is the only laboratory in Poland licensed to work with functional HIV strains; work there gave him confidence in his manual skills. He first came in contact with major league science during his project at Ghent University, Belgium, Department of Molecular Biotechnology, which led to his graduation with a Master Engineer degree in Biotechnology. Finally, he completed his Ph.D. research in Vytautas Magnus University and Center for Innovative Medicine in Lithuania.
Karolina Žilionytė, M.Sc., is a young scientist, specializing in tumor immunology and immunotherapy. Karolina got master degree in Microbiology and Biotechnology at Vilnius University and in 2017 she started PhD studies in biology. In 2017 she has participated in EFIS-EJI South East European Immunology School, where she deepened her knowledge in immunology.
Vita Pašukonienė, Ph.D., is an oncoimmunologist, working in this field more than 20 years. She has graduated from Vilnius University faculty of Natural Sciences and defeated her Ph.D. theses in Immunology in 2003.
Vytautas Kašėta, Ph.D., is a biologist focused on cellular technologies. He has graduated molecular biology bachelor studies in 2004 in the Vilnius University, microbiology and biotechnology master in 2006 and in 2011 defended his Biomedical sciences Ph.D. thesis on Stem Cell Biology in Immunology, Serology, Transplantation section.
